NCT05214482View on ClinicalTrials.gov

A Study of AK112 in Advanced Malignant Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

January 22, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2026

Conditions

Advanced Malignant Tumors

Interventions

DRUG

AK112

IV infusion,Specified dose on specified days

DRUG

AK117

IV infusion,Specified dose on specified days

DRUG

Chemotherapy

IV infusion,Specified dose on specified days

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05214482 - A Study of AK112 in Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter